Navigation Links
bioRASI Completes Acquisition of Ukrainian CRO
Date:3/28/2013

Aventura, FL (PRWEB) March 28, 2013

bioRASI, a full service, global Contract Research Organization (CRO), announced today that it has acquired Sponsors Clinical Research Group, LLC (SCRG), a Ukrainian based regulatory and clinical CRO. SCRG was established in 2004 and has been conducting clinical studies in an extensive range of therapeutic areas including cardiology, neurology, oncology, endocrinology and pulmonology.

“We have been working with SCRG for over a year and have been impressed with the superior expertise of its staff, so it was only natural to consider a more integrated structure,” explained Dr. Boris Reznik, Chairman of bioRASI. “This acquisition enhances bioRASI’s global infrastructure focused on delivering optimized clinical development for our sponsors who are under increasing pressure to accelerate drug development timelines while minimizing costs.”

The acquisition of SCRG addresses the ever-increasing demand for optimizing global clinical trials and builds upon bioRASI’s already commanding presence throughout Eastern Europe.

“While SCRG has been working for many global sponsors and CROs, we have never experienced the powers of project management comparable to that of bioRASI,” explained Dr. Veklych, SCRG’s Executive Director. “An integrated set of tools embodied in the bioRASI Process Infrastructure (BPI) greatly enhances optimized project delivery capabilities. We are excited about being a part of bioRASI’s winning team.”    

About bioRASI
bioRASI is an award-winning Full Service Global CRO providing clinical development services that optimize its sponsors’ scientific, clinical, and business results. bioRASI facilitates obtaining global marketing approval for drugs, biotherapeutics, and medical devices by delivering high quality regulatory and clinical strategies, solutions and services. The Company's unique access to the largest facilities and patient populations worldwide saves clients critical time. bioRASI's services include program optimization, project management, regulatory, clinical, data management and analysis, compliance and audit. bioRASI is headquartered in Aventura, FL and has regional offices and operations across North America and around the world.

Click here for a copy of our White Paper Series.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10578507.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Novira Therapeutics Completes $25 Million Series A Financing
2. BGI-Shenzhen Completes Acquisition of Complete Genomics
3. Amarantus Completes Name Change and CUSIP Change
4. Advanced Cell Diagnostics Completes $12 Million Series B Financing
5. Synthetic Biologics Completes $10.8 Million Private Placement Financing
6. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
7. BioLife Solutions Completes Corporate Facilities Expansion, Build-Out of Additional cGMP Clean Room Manufacturing Suite
8. Cerulean Completes Enrollment of Randomized Phase 2 Study of CRLX101 in Non-Small Cell Lung Cancer
9. China Integrated Energy Inc. Completes Independent Investigation
10. Oxford Finance Completes $271.4 Million Securitization Transaction
11. inVentiv Health Completes Acquisition of Kforce Clinical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... GRAND RAPIDS, Mich. , Dec. 5, 2016 NxGen MDx ... "By bringing the test in house, we,ve been able to improve ... costs down for patients," says Alan Mack , CEO of NxGen ... , , ... increase in test volume has led to more job opportunities at the ...
(Date:12/5/2016)... 5, 2016 The U.S. Biotechnology ... $108 billion of revenue and some $890 billion of ... on global biopharmaceuticals, and this figure is expected to ... lined up these four equities for assessment: Northwest Biotherapeutics ... (NASDAQ: ACAD ), Acorda Therapeutics Inc. (NASDAQ: ...
(Date:12/4/2016)... Dec. 3, 2016  In five studies being presented ... Annual Meeting and Exposition in San Diego ... to improve the delivery of life-saving treatments to patients ... are designed to carry therapies directly to the sites ... could provide a substantial advantage over traditional, systemic methods. ...
(Date:12/2/2016)... , Dec. 2, 2016 More than $4.3 ... 11th Double Helix Medals dinner ( DHMD ). The gala was held ... New York City and honored Alan ... contributions, respectively, to health and medicine and the public understanding ... in 2006, the event has raised $40 million for ...
Breaking Biology Technology:
(Date:11/30/2016)... Nov. 30, 2016  higi SH llc (higi) ... initiative targeting national brands, industry thought-leaders and celebrity ... respective audiences for taking steps to live healthier, ... in 2012, higi has built the largest self-screening ... 38 million people who have conducted over 185 ...
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today ... athletes and their trainers non-invasively measure hemoglobin, ... Pulse Rate, and Respiration Rate in approximately 30 seconds. ... users easy and immediate access to key data about ... of a training regimen. Hemoglobin carries ...
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
Breaking Biology News(10 mins):